Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide to Reverse Resistance to Lenvatinib and PD-1 Inhibitors in Advanced HCC
NCT05831969Phase 2Unknown
- Sponsor
- Shenyang Tenth People's Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lenalidomide in hepatocellular carcinoma (HCC), sponsored by Shenyang Tenth People's Hospital. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05831969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831969.